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The use of PET/CT as an adjunct in radiotherapy planning is an attractive option in head and
neck cancer (HNC) for several reasons. First, with potentially better identification of the
disease extent, i.e., staging, the risk of geographical miss of radiation delivery to the gross
tumor volume is reduced. Second, in characterizing the biological behavior of the disease
for example, areas of hypoxia, rich or poor vascularity, or high cell proliferation, PET/CT can
identify biological target volumes either for escalation of radiation dose or to predict the
requirement for the addition of a radiosensitizer or alternative treatment strategies. 18F-FDG
is the most common tracer used in oncology studies, but many other tracers have been
investigated with several entering clinical practice, although these remain predominantly
in the research domain in HNC.
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TARGETING HYPOXIA
PET/CT imaging can provide a spatial map of the intra-tumoral
distribution of hypoxia before and during radiotherapy using18F-
fluoromisonidazole (18F-FMISO), a nitroimidazole PET tracer
that is reduced and bound to cell constituents under hypoxic
conditions. 18F-FMISO has been shown to be both a predictive
and prognostic biomarker in head and neck cancer (HNC). Sev-
eral studies have shown that the level of hypoxia depicted by
18F-FMISO PET before treatment correlates with loco-regional
failure (Eschmann et al., 2005; Thorwarth et al., 2005; Rischin
et al., 2006). In all tumor types evaluated, poorer outcome (local
control and development of metastases) was observed when a sig-
nificant fraction of the pO2 readings were below 7–10 mm Hg
(Krohn et al., 2008). Tumor retention of 18F-FMISO reflects tissue
pO2 in the radiobiologically relevant range of 1–10 mm Hg and
shows moderate to high correlation with pO2 levels measured with
Eppendorf electrodes (Gagel et al., 2004). 18F-FMISO PET has also
been used to define a hypoxic biological target volume (BTV) and
theoretical planning studies have demonstrated the potential to
dose-escalate to this sub-volume (Rajendran et al., 2006; Thor-
warth et al., 2007; Lee et al., 2008). Lee at al. planned a boost
of 84 Gy to the hypoxic gross tumor volume (GTV; delineated as
areas of 18F-FMISO uptake within the 18F-FDG-PET/CT GTV)
and 70 Gy to the GTV, in 10 patients without exceeding normal
tissue tolerance (Lee et al., 2008). An attempt to deliver 105 Gy to
the hypoxic GTV was only successful in one of two patients with
normal tissue sparing. In a further planning study, Thorwarth et al.
(2007) calculated a potential increase in tumor control probability
from 55.9 to 70.2% by dose-escalating to an 18F-FMISO delineated
hypoxic volume in 13 patients using a dose painting by numbers
(DPBN) strategy compared with a conventional IMRT plan main-
taining iso-toxicity. To date, no clinical studies have been published
with outcome of dose escalation to 18F-FMISO-defined volumes.
One of the limitations of 18F-FMISO imaging in this setting may
be its temporal variability. Nehmeh et al. (2008) have shown that
when patients underwent two baseline 18F-FMISO scans 3 days
apart, a voxel by voxel analysis of putative hypoxic areas revealed
a strong correlation across the two time points in less than half of
patients.
An alternative PET tracer for imaging hypoxia is Cu-diacetyl-
bis(N4-methylthiosemicarbazone) (Cu-ATSM) which can be
labeled with 60/61/62/64Cu isotopes with varying physical and pro-
duction properties. The 64Cu isotope presents the best compro-
mise between adapted physical properties and good production
yield and is showing promise as a non-invasive marker of tumor
hypoxia (Bourgeois et al., 2011). In both normoxic and hypoxic
cells the [Cu(II)-ATSM] complex is reduced by intracellular thi-
ols resulting in an unstable [Cu(I)-ATSM] complex. In normoxic
cells it is re-oxidized to a stable [Cu(II)-ATSM] complex and dif-
fuses out of cells. Under hypoxic conditions, however, the [Cu(I)-
ATSM] slowly dissociates and copper is irreversibly trapped by
intracellular copper chaperone proteins. The uptake of 60Cu-
ATSM has been shown to correlate with tumor pO2 in rat models
(Lewis et al., 1999). In a feasibility study, Chao et al. (2001) demon-
strated a heterogeneous distribution of 60Cu-ATSM within the
GTV of patients with HNC and planned 80 Gy in 35 fractions to
the ATSM-avid tumor sub-volume with 70 Gy in 35 fractions to
the GTV without compromising normal tissue constraints.
IMAGING PROLIFERATION
Accelerated repopulation during radiotherapy for HNC is another
mechanism of radioresistance which adversely affects outcome.
PET tracers which seek to image DNA synthesis have been devel-
oped and may offer an advantage in specificity over 18F-FDG-PET
which is also taken up by peri-tumoral inflammatory cells. 3′-
Deoxy-3′-18F-fluorothymidine (18F-FLT) is a tracer that reflects
the activity of thymidine kinase 1, a key enzyme in DNA synthesis
(Shields et al., 1998) and is taken up by dividing tumor cells but
not by terminally differentiated immune response cells. Troost et
al. have evaluated the role of 18F-FLT in early response assessment
to radiotherapy in 10 patients with HNC (two received concomi-
tant chemotherapy). Patients underwent 18F-FLT PET/CT scan
before and during the second and fourth weeks of radiotherapy.
The GTV delineated on CT decreased significantly in the fourth
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week but not in the initial phase of treatment whereas signifi-
cant changes in SUVmax and SUVmean were observed on 18F-FLT
images as early as 1 week into radiotherapy and decreased even
further before the fourth week of treatment. An arbitrary, fixed
threshold (80%) of the SUVmax was defined such that a tumor
sub-volume could be delineated in at least the first and second
18F-FLT PET scans. Using this 80% isocontour, dose escalation
was demonstrated to be technically feasible, although with only
a modest dose increase (68–74 Gy) in a small sub-volume and
this was only attempted in one patient. Accelerated repopulation
is thought to occur after 4 weeks of radiotherapy but this is not
reflected in 18F-FLT PET uptake during radiation in studies in
HNC. Studies in radiation for squamous cell carcinoma (SCC) of
the esophagus also showed reducing 18F-FLT PET uptake as the
duration of radiation increased. However, interestingly in patients
who experienced a treatment break, increased uptake of 18F-FLT
PET was observed after treatment interruptions which may reflect
accelerated repopulation (Yue et al., 2010).
As hypoxic and proliferative tumor sub-volumes diminish dur-
ing treatment, it is likely that radiation boosts targeted to this area
would need to be delivered early in the treatment course in order
to maintain the temporal and spatial accuracy of such a boost. This
may be best delivered by an up-front boost rather than a simul-
taneous integrated boost for the duration of treatment though
further studies are required to address this question.
INCORPORATING PET/CT INTO RADIATION PLANNING AND
DELIVERY
Although planning radiation delivery to a PET-defined BTV is an
attractive strategy, there are uncertainties relating to the accuracy
of PET/CT in this setting. The potential advantages and disad-
vantages are summarized in Table 1. One of the main areas of
uncertainty relates to segmentation of the PET target volume,
i.e., definition of the ‘edge’ of the target. Five main methods
have been developed. (1) Visual interpretation, which is highly
operator-dependent and susceptible to window-level settings and
interpretation differences (Nishioka et al., 2002; Heron et al., 2004;
Riegel et al., 2006). (2) Isocontouring based on a fixed standard-
ized uptake value (SUV). (3) Fixed threshold of maximum tumor
signal intensity (40 or 50%) (Ciernik et al., 2003; Nestle et al., 2005;
Paulino et al., 2005). A major disadvantage of using the maximum
tumor SUV is that it is highly dependent on contrast recovery
and noise properties that vary by scanners and reconstructive
protocols, therefore, superior techniques have been sought. (4)
Variable threshold based on adaptive signal-to-background ratio
(SBR) (Daisne et al., 2004). (5) Iterative background-subtracted
relative-threshold using watershed transformation and hierarchi-
cal cluster analysis in which the optimal relative-threshold depends
on the lesion size not the SBR (Geets et al., 2007a,b; van Dalen et al.,
2007).
The first four of these methods have been compared in a plan-
ning study of 78 patients which found that both the volume
and shape of GTV was influenced by the segmentation method
(Schinagl et al., 2007). The visual method volumes were close to
CT-defined GTV and all automated volumes were smaller. A fixed
SUV of 2.5 failed to identify the GTV in 45% of cases and in 29–
64% of patients more than 20% of PET-based GTV was outside the
Table 1 | Summary of potential advantages and disadvantages to the
use of 18FDG-PET in radiotherapy planning for head and neck cancer.
Advantages Disadvantages
May reduce inter-observer variation in
GTV delineation (Ciernik et al., 2003;
Riegel et al., 2006)
Limited spatial resolution
Reduces size of GTV (Daisne et al., 2004) Lack of standardized method
for signal segmentation
Identify tumor or LN missed by CT/MRI False positive PET readings
due to inflammation
Identify parts of GTV potentially requiring
additional radiation dose
clinical/CT-based GTV although it is unknown if this represents
a false positive due to peri-tumoral inflammation. A threshold of
50% maximum SUV (SUVmax) produced a GTV volume most
similar to the SBR method which has been shown to be more
similar to pathological volumes than CT or MRI. All three modal-
ities, however, failed to identify superficial tumor extension due
to a lack of spatial resolution (Daisne et al., 2004). Although the
gradient-based segmentation method has been shown to be more
accurate than the SBR method when compared with macroscopic
extent of resected laryngeal tumors, neither of these techniques
are widely available outside the center where they were developed
(Geets et al., 2007a,b).
Moule et al. (2010) compared functional volumes delineated
by SUV cut off (2.5, 3.0, 3.5, and 4.0 bodyweight g/ml) and per-
centage of the SUVmax (30, 35, 40, 45, and 50%) thresholds on
18F-FDG-PET scans acquired at 0, 10, 44, and 66 Gy of radiation.
Using the SUVmax method, the software was unable to differenti-
ate effectively between tumor and background uptake after 36 Gy
and the delineated volumes increased as the delivered radiation
dose increased. In a planning study based on the same dataset
using an adaptive iterative algorithm weighted according to the
mean SUV within the ROI to delineate target volumes, no signifi-
cant reduction in the primary target volumes was observed during
radiotherapy (Moule et al., 2011).
Due to the sub-optimal outcome for a significant proportion
of patients with HNC, PET-defined BTVs are an attractive target
for dose escalation. The dose required to overcome radioresistance
within the target volume is unknown. Radiobiological modeling
may predict such doses, however, current treatment algorithms in
the head and neck region are already close to patient tolerance.
Two clinical studies have been published evaluating the outcome
of 18F-FDG-PET-based dose escalation. In 2007, Madani et al.
(2007) reported a phase 1 trial boosting to two planned dose levels
of 25 and 30 Gy delivered in 10 fractions followed by 22 fractions
of 2.16 Gy using IMRT (total dose 72.5 or 77.5 Gy in 32 fractions).
Twenty-three patients were enrolled at dose level 1 and 18 at level 2.
Two cases of dose-limiting toxicity occurred at dose level 1 (Grade
4 dermatitis and Grade 4 dysphagia) and a treatment-related death
at dose level 2. Despite the doses achieved and toxicity experienced,
in four of nine patients, the site of relapse was within the boosted
18F-FDG-PET-delineated region. More recently, the same group
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has reported results of a phase 1 trial of DPBN delivering a mean
dose of 80.9 Gy to the high dose CTV (seven patients) or 85.9 Gy
to the GTV (14 patients) in 32 fractions (Duprez et al., 2011).
For each patient the first 10 fractions of treatment comprised a
voxel intensity-based (DPBN) IMRT plan using a baseline 18F-
FDG-PET scan, fractions 11–20 used the same technique based
on an 18F-FDG-PET scan acquired after the eighth fraction and
the remaining fractions were delivered using a uniform dose IMRT
plan. The adaptive planning reduced the irradiated volume of both
target and normal tissue, particularly in dose level 2 where dose
was escalated to GTV. There was no grade 4 acute toxicity, how-
ever, only 9 out of 21 patients received concomitant chemotherapy
and further follow-up has identified mucosal ulcers as the dose-
limiting toxicity (Madani et al., 2011). Six cases of mucosal ulcers
were observed at a latency of 4–10 months following treatment,
of which five were observed at dose level II (median total dose of
85.9 Gy to the GTV). This led to the establishment of dose level I
(median total dose of 80.9 Gy to the high dose CTV) as the maxi-
mum tolerated dose in that trial and highlights the importance of
longer-term follow-up in these studies.
18F-FDG-PET AS A BIOMARKER IN HNC
In addition to a role in target definition, 18F-FDG-PET imaging
can identify patients who are less likely to respond to current treat-
ment algorithms and may benefit from alternative treatments, dose
escalation, or early salvage options. Several published studies have
demonstrated this role using baseline 18F-FDG-PET parameters
(Inokuchi et al., 2011; Higgins et al., 2012; Liu et al., 2012) or
18F-FDG-PET imaging acquired 2–4 months following comple-
tion of treatment (Yao et al., 2005; Krabbe et al., 2009; Gupta et al.,
2010; Moeller et al., 2010; Ceulemans et al., 2011), Table 2. In a
study by Higgins et al. a higher baseline SUVmean in a cohort of
88 patients was predictive of DFS (P = 0.01), Table 2 (Higgins
et al., 2012). Patients with a SUVmean below 7 (median value for
the cohort) had a prolonged 2 years DFS (82 vs. 58%, P = 0.03)
compared with those with a baseline SUVmean above 7. Neither
SUVmax in the primary tumor or LN or total lesion glycolysis
(SUVmean× tumor volume) was prognostic for any of the clinical
endpoints evaluated. In contrast, in a larger study, Inokuchi et al.
(2011) found baseline SUVmax to be predictive of outcome with a
nodal SUVmax≥ 6 predicting for a poorer 3 years DFS (44 vs. 69%
P = 0.004). Additionally, in the group with a nodal SUVmax≥ 6,
those undergoing a planned neck dissection following CRT had a
more favorable outcome than those who were observed (P = 0.04).
Both these studies included patients with all sub-types of HNC.
Monitoring of early response during treatment could allow
treatment modification or adaptation and this has been shown
in a proof-of-principle study by Geets et al. (2007a). Ten patients
with pharyngo-laryngeal SCC treated with CRT were subjected
to CT, MRI, and 18F-FDG-PET during treatment (at baseline and
after mean prescribed doses of 14, 25, 35, and 45 Gy). Throughout
the course of radiotherapy, GTVs. delineated (using a gradient-
based method) on 18F-FDG-PET substantially decreased and were
always smaller than those defined with CT and MRI (P < 0.001).
Table 2 | Summary of studies evaluating 18F-FDG-PET as a predictor of response to CRT in patients with HNC.
Author n 18F-FDG-PET Diagnostic accuracy for residual disease (%) Survival prediction
Sensitivity Specificity PPV NPV Accuracy
Gupta et al. (2010) 57 9 weeks PT Primary site LRC and OS
50 91.8 50 91.8 86
Neck
62.5 98 83.3 94.1 93
Ceulemans et al. (2011) 40 47 Gy 28.6 81.8 80 31 42.5 None
4 months PT 78.6 75 88 60 77.5 OS
Krabbe et al. (2009) 48 3, 6, 9, 12 month PT 100 43 51 100
McCollum et al. (2004) 40 After ICT 100 65 27 100 69
After CRT 67 53 46 73 58
Moeller et al. (2010) 98 8 weeks PT Primary site SUVmax and OS SUVmax ≥6
50 85 50 92
Lymph nodes
25 50 6 85
Yao et al. (2005) 53 15 weeks PT 100 94 43 100
Hentschel et al. (2011) 37 10–20 Gy ∆SUVmax10/20 ≥50% predicts 2 years OS
Higgins et al. (2012) 88 Baseline SUVmean and DFS
Inokuchi et al. (2011) 178 Baseline SUVmax and DFS, NPFS, DMFS
Liu et al. (2012) 75 Baseline SUVmax and 5-years DFS, LFFS
Yoon et al. (2011) 21 After ICT SUVmax <4.8, or ↓65% and CR
PPV, positive predictive value; NPV, negative predictive value; n, number of patients in study; LRC, loco-regional control; OS, overall survival; PT, post-treatment; ICT,
induction chemotherapy; SUVmean, mean standardized uptake value; SUVmax, maximum SUV; DFS, disease-free survival; NPFS, nodal progression-free survival; DMFS,
distant metastasis-free survival; LFFS, local failure-free survival.
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During treatment this resulted in a progressive reduction of irra-
diated volumes by 15–40% compared with standard CT-based
volumes delineated pre-treatment. This adaptive approach only
impacted the high dose volumes (≥V90) with little additional
sparing of organs at risk (OAR).
The optimum timing of 18F-FDG-PET imaging following treat-
ment is uncertain due to 18F-FDG uptake in non-malignant
inflammatory tissue which complicates interpretation. In a study
by Greven et al., 45 patients with HNC underwent 18F-FDG-PET
scans at 1, 4, 12, and 24 months following radiotherapy for HNC.
Specificity for detection of residual or recurrent tumor was high at
both 1 and 4 months (95 and 90%, respectively), however, sensitiv-
ity increased from 59% at 1 month to 100% at 4 months suggesting
the optimum time for post-treatment assessment is between 1 and
4 months (Greven et al., 2001; Bussink et al., 2010). Encouraging
results have recently been published for 18FDG-PET in response
assessment following definitive chemoradiotherapy (CRT) in pre-
dicting loco-regional control and improved survival in those with
a negative scan (at a median of 9 weeks post-CRT) (Gupta et al.,
2010), and in several other studies, Table 2.
Ceulemans et al. (2011) have evaluated whether an 18F-FDG-
PET scan during treatment (after 47 Gy) could replace one at
4 months post-treatment as a predictive and prognostic bio-
marker. Both PET scans had a high specificity and PPV, however,
the sensitivity of the post-treatment scan was much higher than
during treatment (79 vs. 29%). Additionally there was a sig-
nificant difference in overall survival between patients with a
complete response vs. a non-complete response on PET scan-
ning at 4 months (92 vs. 50%) but not after 47 Gy. In contrast,
an early reduction in SUVmax during treatment may be predic-
tive of outcome. Hentschel et al. (2011) evaluated serial 18F-
FDG-PET scans at three time points during CRT comparing
changes in SUV with baseline. In their series of 37 patients
a reduction of SUVmax of ≥50% after 10–20 Gy of radiation
(∆SUVmax10/20≥ 50%) was predictive of 2 years OS (88 vs. 38%,
P = 0.02), and a below median volume of disease defined on
baseline PET was also predictive of 2 year OS (83 vs. 34%,
P = 0.02).
PET/CT IN THE CONTEXT OF INDUCTION CHEMOTHERAPY
The majority of published studies have been undertaken in
patients receiving definitive CRT alone. As induction chemother-
apy (IC) is increasingly used, it is unclear how applicable these
PET-based response prediction data are for this population. Only
two studies have evaluated the role of 18F-FDG-PET imaging in
HNC patients undergoing IC in addition to CRT. In the first,
McCollum et al. (2004) evaluated 33 patients undergoing 18F-
FDG-PET imaging following IC and 37 with imaging 4–12 weeks
after completion of CRT. Twenty-six patients had a repeat biopsy
after IC against which the18F-FDG-PET findings were compared.
18F-FDG-PET was found to have a high sensitivity and moder-
ate specificity in the setting but these findings were not related
to outcome. The overall accuracy of PET for predicting persistent
tumor at the primary site after IC was 69% (95% CI, 51–87%)
and NPV 100% (95% CI, 78–100%), Table 2. In the second study,
Yoon et al. showed that a SUVmax of 4.8 on interim 18F-FDG-PET
could predict clinical complete response after CRT (100 vs. 20%,
p= 0.001), PFS (median, not reached vs. 8.5 months, p< 0.001),
and OS (median, not reached vs. 12.0 months, p= 0.001). A 65%
decrease in SUVmax after IC from baseline in the same study could
also predict complete clinical response after CRT (100 vs. 33.3%,
p= 0.003), PFS (median, not reached vs. 8.9 months, p< 0.001),
and OS (median, not reached vs. 24.4 months, p= 0.001). Of
note, only patients with a partial response to IC as determined
by Response Evaluation Criteria In Solid Tumors (RECIST) were
included in this study.
FIGURE 1 | Comparative axial images from contrast-enhanced CT (left), and 18F-FDG-PET/CT (right) for a patient withT2N2b SCC tonsil before (top)
and after (bottom) induction chemotherapy.
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FIGURE 2 | Complexity of implementing functional imaging into the
management of head and neck cancer. Each building block represents a
challenge to be overcome in order to validate promising data and perform
successful multi-center trials. Data acquisition (blue) needs to be standardized
before the influence of biological factors (red) can be interpreted. Data
transfer and widely available multi-modality viewing platforms (green) need to
be developed with rigors QA and robust data (orange) before ultimately,
multi-center trials can be undertaken.
Our own experience has shown that 18F-FDG-PET can alter
the conventionally defined GTV and clinical target volume (CTV)
(Newbold et al., 2008). A subsequent feasibility study is in progress
investigating how tumor metabolism changes during treatment
with IC followed by CRT and whether 18F-FDG-PET imaging is
able to identify a relevant BTV which may benefit from treatment
intensification strategies. Patients undergo standard anatomical
CT and MRI and functional imaging with 18F-FDG-PET/CT, pre-
IC, post IC, and at 3 and 6 months post completion of treatment.
It was initially anticipated that it would be possible to delineate
a BTV on both functional and anatomical imaging at the first
two time points as a minimum. A significantly larger reduction in
metabolic signal than in the volume defined on CT or anatomical
MRI sequences has been observed which may imply that 18F-FDG-
PET is a more sensitive method for assessing early response to
treatment than conventional anatomical imaging. However, ini-
tial analysis shows that the biological response to IC (Figure 1) is
so marked that it will be difficult, or even impossible, to delineate
small volume residual disease during radiotherapy planning. In
the majority of patients a metabolic signal is no longer detected on
18F-FDG-PET/CT images following IC. This may represent stun-
ning and a false negative due to metabolic switch off, but this is
unlikely as all the 18F-FDG-PET images were acquired more than
10 days after administration of chemotherapy. It does though, have
significant implications for image-guided radiotherapy strategies
that aim to deliver radiation boosts to BTV defined on functional
imaging. Based on these early observations, such a boost volume
would have to be defined on the original baseline images acquired
before the initiation of IC. The physical and biological relevance
of this BTV at the start of CRT (following 6 weeks of IC) is far
from clear.
LIMITATIONS OF PET/CT IMAGING IN RADIATION PLANNING
Functional imaging and its application to radiotherapy is a rapidly
expanding field with new modalities and techniques constantly
developing and evolving. As technologies improve, so it will be
important to pay careful attention to their implementation. It is
crucial, therefore, that good collaborative links are maintained
with diagnostic physicians in order to assure correct interpretation
of the functional imaging acquired. This will be particularly rele-
vant as scanners are incorporated into RT departments and images
acquired solely for RT planning purposes. It may also become nec-
essary to develop improved quantitative, rather than qualitative,
assessment of the response to treatment. For example, the con-
cept of a ‘metabolic response to treatment’ where the criteria of a
change >1 SUV and a 20–30% relative change in SUV are both
met is less likely to be a chance finding than either criterion alone
(de Langen et al., 2012).
Another important limitation is the finite resolution of PET.
Biological image-guided radiotherapy aims at specifically irra-
diating biologically relevant sub-volumes within the tumor and
requires functional imaging to be sensitive and specific enough
to image the biological pathway of interest such as tumor
metabolism. Preclinical studies have shown discrepancies between
imaging with a small-animal PET scanner with a spatial resolu-
tion of 2.7 mm and the underlying microscopic reality represented
by autoradiography (Christian et al., 2009). Such a discrepancy
means the macroscopic assessment of tumors with molecular
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imaging might not necessarily reflect their microregional distri-
bution (Bussink et al., 2010). Additionally, many microregional
tumor areas are likely to co-exist within one PET voxel, and have
varied exposure to acute and chronic hypoxia. Negative scan find-
ings cannot, therefore, exclude the presence of microscopic tissue
involvement, and precise anatomic localization of the signal can
be difficult in certain anatomic regions (Fletcher et al., 2008).
As the set-up tolerance is up to 3 mm for patients with HNC
immobilized in TP masks, caution should also be given to dose
prescriptions to a voxel of approximately 5 mm size as its precise
location intra- or inter-fraction cannot be assured. Heterogeneous
dose prescriptions varied by voxel may not be possible with current
delivery systems. Furthermore, the microenvironment of treated
and untreated tumors changes with time. This has implications for
signal validation with repeat imaging and more work is required
in this area to quantify this uncertainty particularly in the use of
functional imaging for DPBN.
Despite a decade of activity in this field and thousands of
peer-reviewed publications demonstrating the utility of molec-
ular and functional imaging, this is yet to be implemented into
routine clinical practice. The reason for this is multi-factorial
and relates to much of the data being generated from single
institutions series with variations in imaging modality, sequence
acquisition, data processing, and analysis tools. The next challenge
is implementing PET imaging and tackling the associated uncer-
tainties, Figure 2. As preliminary findings are validated in larger
studies, so attention to standardization of protocols and image
processing and data analysis must occur. This is necessary not
only for implementing findings from studies performed at other
institutions but, most importantly, in the design of multi-center
trials which must include rigorous QA (quality assurance). For
example, metabolic treatment volumes are often defined in rela-
tion to SUVmax, which is highly dependent on contrast recovery
and noise properties that vary across scanners and reconstructive
protocols. The European association of nuclear medicine (EANM)
have published guidelines in an attempt to standardize PET image
acquisition, processing and reporting, however, these are yet to
be fully adopted (Boellaard et al., 2010). Thresholds for meta-
bolic change using 18F-FDG-PET are approximately−34 to+52%
for individual centers and −26 to +39% after centralized QA
(Velasquez et al., 2009). Hence there is a need for standardiza-
tion in relation to the use of SUVs and SUV changes in studies of
treatment response assessments (Boellaard, 2011).
CONCLUSION
It is likely that PET/CT as a modality with multiple tracers will
continue to have a role in determining treatment strategies for
HNC. Defining BTVs to target for radiation dose escalation will
only be one aspect with tumor phenotyping using PET/CT para-
meters as biomarkers another, providing methods of stratification
of patients based on likelihood of response at baseline assessment.
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